PT4076662T - PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS - Google Patents
PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTSInfo
- Publication number
- PT4076662T PT4076662T PT208293654T PT20829365T PT4076662T PT 4076662 T PT4076662 T PT 4076662T PT 208293654 T PT208293654 T PT 208293654T PT 20829365 T PT20829365 T PT 20829365T PT 4076662 T PT4076662 T PT 4076662T
- Authority
- PT
- Portugal
- Prior art keywords
- cancer agents
- derivatives useful
- pyrazolyl derivatives
- pyrazolyl
- useful
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962951400P | 2019-12-20 | 2019-12-20 | |
| PCT/CN2020/125425 WO2021120890A1 (en) | 2019-12-20 | 2020-10-30 | Pyrazolyl derivatives useful as anti-cancer agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT4076662T true PT4076662T (en) | 2024-04-18 |
Family
ID=76477081
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT208293654T PT4076662T (en) | 2019-12-20 | 2020-12-17 | PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US11702409B2 (en) |
| EP (2) | EP4344702A3 (en) |
| JP (3) | JP7726883B2 (en) |
| KR (1) | KR20220114064A (en) |
| CN (1) | CN114929342A (en) |
| AR (1) | AR120855A1 (en) |
| AU (1) | AU2020410531B2 (en) |
| CA (1) | CA3165148A1 (en) |
| CL (1) | CL2022001625A1 (en) |
| CO (1) | CO2022008344A2 (en) |
| CR (1) | CR20220281A (en) |
| DK (1) | DK4076662T3 (en) |
| DO (1) | DOP2022000124A (en) |
| EC (1) | ECSP22047876A (en) |
| ES (1) | ES2987196T3 (en) |
| FI (1) | FI4076662T3 (en) |
| HR (1) | HRP20240513T1 (en) |
| HU (1) | HUE066235T2 (en) |
| IL (1) | IL293893A (en) |
| JO (1) | JOP20220155A1 (en) |
| LT (1) | LT4076662T (en) |
| MA (1) | MA58004B1 (en) |
| MX (1) | MX2022007350A (en) |
| PE (1) | PE20221910A1 (en) |
| PH (1) | PH12022551454A1 (en) |
| PL (1) | PL4076662T3 (en) |
| PT (1) | PT4076662T (en) |
| RS (1) | RS65419B1 (en) |
| SI (1) | SI4076662T1 (en) |
| TW (1) | TW202136241A (en) |
| UY (1) | UY38990A (en) |
| WO (2) | WO2021120890A1 (en) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020085493A1 (en) | 2018-10-26 | 2020-04-30 | 大鵬薬品工業株式会社 | Novel indazole compound or salt thereof |
| UA129778C2 (en) | 2019-10-28 | 2025-07-30 | Мерк Шарп Енд Доум Елелсі | LOW-MOLECULAR INHIBITORS OF G12C-MUTANT KRAS |
| US12479834B2 (en) | 2019-11-29 | 2025-11-25 | Taiho Pharmaceutical Co., Ltd. | Phenol compound or salt thereof |
| EP4076661A1 (en) | 2019-12-20 | 2022-10-26 | Nuevolution A/S | Compounds active towards nuclear receptors |
| KR20230019462A (en) | 2020-06-02 | 2023-02-08 | 베링거 인겔하임 인터내셔날 게엠베하 | Cyclic 2-amino-3-cyanothiophene and derivatives for cancer treatment |
| TW202227405A (en) * | 2020-08-24 | 2022-07-16 | 以色列商安道麥馬克西姆有限公司 | Process for preparation of substituted pyrazoles |
| CA3187757A1 (en) | 2020-09-03 | 2022-03-24 | Ethan AHLER | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| PE20231207A1 (en) | 2020-09-15 | 2023-08-17 | Revolution Medicines Inc | INDOLIC DERIVATIVES AS RAS INHIBITORS IN CANCER TREATMENT |
| KR20230094198A (en) | 2020-09-23 | 2023-06-27 | 에라스카, 아이엔씨. | Tricyclic pyridones and pyrimidones |
| BR112023007912A2 (en) * | 2020-10-30 | 2024-01-02 | Novartis Ag | CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR COMPOUND |
| WO2022133345A1 (en) | 2020-12-18 | 2022-06-23 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| WO2022133731A1 (en) * | 2020-12-22 | 2022-06-30 | Novartis Ag | Pharmaceutical combinations comprising a kras g12c inhibitor and uses of a kras g12c inhibitor and for the treatment of cancers |
| CA3205008A1 (en) * | 2020-12-22 | 2022-06-30 | Novartis Ag | Pharmaceutical combinations comprising a kras g12c inhibitor and uses of a kras g12c inhibitor for the treatment of cancers |
| MX2023013085A (en) | 2021-05-05 | 2023-11-16 | Revolution Medicines Inc | Ras inhibitors. |
| PE20240089A1 (en) | 2021-05-05 | 2024-01-16 | Revolution Medicines Inc | RAS INHIBITORS FOR CANCER TREATMENT |
| WO2022246459A1 (en) * | 2021-05-19 | 2022-11-24 | Genentech, Inc. | Combination therapy |
| KR20240024928A (en) * | 2021-06-23 | 2024-02-26 | 노파르티스 아게 | Pyrazolyl derivatives as inhibitors of KRAS mutant proteins |
| TW202317100A (en) | 2021-06-23 | 2023-05-01 | 瑞士商諾華公司 | Pharmaceutical combinations comprising a kras g12c inhibitor and uses thereof for the treatment of cancers |
| KR20240041917A (en) | 2021-07-27 | 2024-04-01 | 도레이 카부시키가이샤 | Medicines for the treatment and/or prevention of cancer |
| WO2023031781A1 (en) | 2021-09-01 | 2023-03-09 | Novartis Ag | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
| AR127308A1 (en) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | RAS INHIBITORS |
| US12110276B2 (en) | 2021-11-24 | 2024-10-08 | Genentech, Inc. | Pyrazolo compounds and methods of use thereof |
| US12275745B2 (en) | 2021-11-24 | 2025-04-15 | Genentech, Inc. | Therapeutic compounds and methods of use |
| WO2023099592A1 (en) * | 2021-12-01 | 2023-06-08 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| CR20240233A (en) | 2021-12-01 | 2024-07-17 | Univ Vanderbilt | 2-AMINO-3-CYANO-CANCELLED THIOPHENES AND DERIVATIVES FOR CANCER TREATMENT |
| TW202340214A (en) | 2021-12-17 | 2023-10-16 | 美商健臻公司 | Pyrazolopyrazine compounds as shp2 inhibitors |
| MX2024007780A (en) | 2021-12-22 | 2024-09-11 | Univ California | COVALENT BINDING INHIBITORS OF G12S, G12D AND/OR G12E MUTANTS OF K-RAS GTPASE. |
| MX2024008337A (en) | 2021-12-29 | 2024-07-30 | Psy Therapeutics Inc | Inhibiting monoacylglycerol lipase (magl). |
| WO2023143605A1 (en) * | 2022-01-31 | 2023-08-03 | Novartis Ag | Process for the synthesis of pyrazolyl derivatives useful as anti-cancer agents |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| CN119136806A (en) | 2022-03-08 | 2024-12-13 | 锐新医药公司 | Methods for treating immune-refractory lung cancer |
| KR20240167633A (en) | 2022-03-31 | 2024-11-27 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | Pharmaceutical composition for the treatment of tumors |
| WO2023199180A1 (en) | 2022-04-11 | 2023-10-19 | Novartis Ag | Therapeutic uses of a krasg12c inhibitor |
| US11878958B2 (en) | 2022-05-25 | 2024-01-23 | Ikena Oncology, Inc. | MEK inhibitors and uses thereof |
| CN120504682A (en) | 2022-06-10 | 2025-08-19 | 锐新医药公司 | Macrocyclic RAS inhibitors |
| WO2024040131A1 (en) | 2022-08-17 | 2024-02-22 | Treeline Biosciences, Inc. | Pyridopyrimidine kras inhibitors |
| WO2024081674A1 (en) | 2022-10-11 | 2024-04-18 | Aadi Bioscience, Inc. | Combination therapies for the treatment of cancer |
| IL320639A (en) | 2022-11-09 | 2025-07-01 | Revolution Medicines Inc | Compounds, complexes, and methods for their preparation and of their use |
| CN120225197A (en) | 2022-11-18 | 2025-06-27 | 诺华股份有限公司 | Drug combinations and their uses |
| CN121039137A (en) | 2022-11-21 | 2025-11-28 | 树线生物科学公司 | Spirocyclic dihydropyranopyrimidine KRas inhibitors |
| WO2024173761A1 (en) | 2023-02-17 | 2024-08-22 | Ikena Oncology, Inc. | Combinations comprising mek inhibitors for use in the treatment of cancer |
| KR20250164828A (en) | 2023-03-30 | 2025-11-25 | 레볼루션 메디슨즈, 인크. | Composition for inducing RAS GTP hydrolysis and use thereof |
| WO2024209717A1 (en) | 2023-04-06 | 2024-10-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Pharmaceutical composition for treating tumors |
| WO2024211712A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| AU2024253668A1 (en) | 2023-04-07 | 2025-11-13 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2024215863A2 (en) * | 2023-04-13 | 2024-10-17 | Psy Therapeutics, Inc. | Inhibiting monoacylglycerol lipase (magl) |
| US20240352038A1 (en) | 2023-04-14 | 2024-10-24 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| CN121100123A (en) | 2023-04-14 | 2025-12-09 | 锐新医药公司 | Crystalline form of Ras inhibitors |
| WO2024220470A1 (en) | 2023-04-17 | 2024-10-24 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof in the treatment of proliferative disorders |
| TW202508595A (en) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | Combination therapy for a ras related disease or disorder |
| CN116478141B (en) * | 2023-06-20 | 2023-10-24 | 药康众拓(江苏)医药科技有限公司 | Deuterated KRAS inhibitor drug and application thereof |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| TW202528315A (en) | 2023-09-21 | 2025-07-16 | 美商樹線生物科學公司 | Spirocyclic dihydropyranopyridine kras inhibitors |
| WO2025067459A2 (en) | 2023-09-29 | 2025-04-03 | D3 Bio (Wuxi) Co., Ltd. | Therapies for the treatment of cancer |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202535891A (en) | 2023-10-20 | 2025-09-16 | 美商默沙東有限責任公司 | Small molecule inhibitors of kras proteins |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025202971A1 (en) | 2024-03-27 | 2025-10-02 | Novartis Ag | Kras g12c inhibitor for use for the treatment of non-small cell lung cancer |
| WO2025203012A1 (en) | 2024-03-27 | 2025-10-02 | Novartis Ag | Kras g12c inhibitor for use for the treatment of non-small cell lung cancer |
| US12358315B1 (en) | 2024-03-29 | 2025-07-15 | Max Co., Ltd. | Long medium |
| WO2025215527A2 (en) | 2024-04-10 | 2025-10-16 | Novartis Ag | Pharmaceutical combinations and uses thereof |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025245127A1 (en) | 2024-05-21 | 2025-11-27 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1199600A (en) * | 1998-10-02 | 2000-04-26 | Board Of Trustees Of The University Of Illinois, The | Estrogen receptor ligands |
| CL2004000234A1 (en) | 2003-02-12 | 2005-04-15 | Biogen Idec Inc | DERIVATIVE COMPOUNDS 3- (PIRIDIN-2-IL) -4-HETEROARIL-PIRAZOL SUBSTITUTED, ANTAGONISTS OF AIK5 AND / OR AIK4; PHARMACEUTICAL COMPOSITION AND USE OF THE COMPOUND IN THE TREATMENT OF FIBROTIC DISORDERS AS SCLERODERMIA, LUPUS NEFRITICO, CICATRIZACION DE HERID |
| EP1786803A1 (en) | 2004-08-31 | 2007-05-23 | Biogen Idec MA, Inc. | Pyrimidinylpyrazoles as tgf-beta inhibitors |
| TW200639163A (en) * | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
| MX2008000141A (en) * | 2005-06-27 | 2008-04-07 | Exelixis Inc | Imidazole based lxr modulators. |
| WO2007105058A2 (en) * | 2006-03-16 | 2007-09-20 | Pfizer Products Inc. | Pyrazole compounds |
| EP2170337A4 (en) | 2007-06-28 | 2013-12-18 | Abbvie Inc | Novel triazolopyridazines |
| US7897619B2 (en) * | 2007-07-17 | 2011-03-01 | Amgen Inc. | Heterocyclic modulators of PKB |
| KR20100038119A (en) * | 2007-08-01 | 2010-04-12 | 화이자 인코포레이티드 | Pyrazole compounds and their use as raf inhibitors |
| DK2324008T3 (en) * | 2008-07-24 | 2012-07-23 | Nerviano Medical Sciences Srl | Diarylpyrazole as protein kinase inhibitors |
| WO2010108268A1 (en) * | 2009-03-23 | 2010-09-30 | Merck Frosst Canada Ltd. | Heterocyclic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| WO2012016993A1 (en) * | 2010-08-03 | 2012-02-09 | Nerviano Medical Sciences S.R.L. | Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents |
| US9226923B2 (en) * | 2011-07-27 | 2016-01-05 | Nanjing Allgen Pharma Co. Ltd. | Spirocyclic molecules as protein kinase inhibitors |
| US20150087628A1 (en) | 2012-04-10 | 2015-03-26 | The Regents Of The University Of California | Compositions and methods for treating cancer |
| CA2869954C (en) | 2012-04-20 | 2023-01-03 | Advinus Therapeutics Limited | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof in medical conditions related to modulation of bruton's tyrosine kinase activity |
| AU2014239542A1 (en) | 2013-03-15 | 2015-10-01 | Araxes Pharma Llc | Covalent inhibitors of KRas G12C |
| WO2015054572A1 (en) | 2013-10-10 | 2015-04-16 | Araxes Pharma Llc | Inhibitors of kras g12c |
| CA2933107C (en) | 2014-01-09 | 2022-06-21 | Merck Patent Gmbh | Pyrimidine pyrazolyl derivatives and their use as irak inhibitors |
| EA201792214A1 (en) | 2015-04-10 | 2018-01-31 | Араксис Фарма Ллк | COMPOUNDS OF SUBSTITUTE QUINAZOLINE |
| US10730867B2 (en) | 2015-09-28 | 2020-08-04 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| EP3356339A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| JP6770580B2 (en) | 2016-01-26 | 2020-10-14 | 杭州華東医薬集団生物医薬有限公司Ｈａｎｇｚｈｏｕ Ｈｕａｄｏｎｇ Ｍｅｄｉｃｉｎｅ Ｇｒｏｕｐ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． | Pyrrolopyrimidine 5-membered ring aza cyclic derivative and its use |
| KR102444509B1 (en) | 2016-05-18 | 2022-09-19 | 미라티 테라퓨틱스, 인크. | KRAS G12C inhibitor |
| US10377743B2 (en) | 2016-10-07 | 2019-08-13 | Araxes Pharma Llc | Inhibitors of RAS and methods of use thereof |
| CN108069955B (en) * | 2016-11-14 | 2021-04-06 | 江苏恒瑞医药股份有限公司 | 3-pyridyl-4-benzothiazolylpyrazole derivatives, preparation method and medical application thereof |
| JP2020500177A (en) * | 2016-11-14 | 2020-01-09 | ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． | 3,4-Bipyridylpyrazole derivative, its production method and its medical application |
| EP3558955B1 (en) | 2016-12-22 | 2021-08-11 | Amgen Inc. | Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer |
| EP3573966A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused n-heterocyclic compounds and methods of use thereof |
| WO2018140514A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer |
| CN110382482A (en) | 2017-01-26 | 2019-10-25 | 亚瑞克西斯制药公司 | Condensed miscellaneous-Heterobicyclic compounds and its application method |
| EP3573971A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
| WO2018140599A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
| JOP20190186A1 (en) | 2017-02-02 | 2019-08-01 | Astellas Pharma Inc | Quinazoline compound |
| KR101956815B1 (en) * | 2017-02-14 | 2019-03-12 | 한국화학연구원 | Triazolo-pyridazine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating Bruton's tyrosine kinase activity related diseases containing the same as an active ingredient |
| JOP20190272A1 (en) | 2017-05-22 | 2019-11-21 | Amgen Inc | Kras g12c inhibitors and methods of using the same |
| TW201900633A (en) | 2017-05-25 | 2019-01-01 | 美商亞瑞克西斯製藥公司 | KRAS covalent inhibitor |
| EA202091186A1 (en) | 2017-11-15 | 2020-10-01 | Мирати Терапьютикс, Инк. | KRas G12C INHIBITORS |
| WO2019136147A1 (en) * | 2018-01-03 | 2019-07-11 | The Board Of Trustees Of The University Of Illinois | Toll-like receptor signaling inhibitors |
| SG11202008029UA (en) * | 2018-02-23 | 2020-09-29 | Samumed Llc | 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof |
| AU2019262589B2 (en) * | 2018-05-04 | 2022-07-07 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| MX2020011907A (en) | 2018-05-10 | 2021-01-29 | Amgen Inc | Kras g12c inhibitors for the treatment of cancer. |
| ES2938987T3 (en) * | 2018-06-01 | 2023-04-18 | Amgen Inc | KRAS G12c inhibitors and methods of use thereof |
| JP2022536692A (en) * | 2019-06-11 | 2022-08-18 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | Adeno-associated viral vector delivery of antibodies for the treatment of diseases mediated by dysregulated plasma kallikrein |
-
2020
- 2020-10-30 WO PCT/CN2020/125425 patent/WO2021120890A1/en not_active Ceased
- 2020-12-17 PH PH1/2022/551454A patent/PH12022551454A1/en unknown
- 2020-12-17 CR CR20220281A patent/CR20220281A/en unknown
- 2020-12-17 WO PCT/IB2020/062144 patent/WO2021124222A1/en not_active Ceased
- 2020-12-17 RS RS20240437A patent/RS65419B1/en unknown
- 2020-12-17 EP EP24151713.5A patent/EP4344702A3/en active Pending
- 2020-12-17 PE PE2022001123A patent/PE20221910A1/en unknown
- 2020-12-17 EP EP20829365.4A patent/EP4076662B1/en active Active
- 2020-12-17 US US17/125,335 patent/US11702409B2/en active Active
- 2020-12-17 UY UY0001038990A patent/UY38990A/en not_active Application Discontinuation
- 2020-12-17 FI FIEP20829365.4T patent/FI4076662T3/en active
- 2020-12-17 PL PL20829365.4T patent/PL4076662T3/en unknown
- 2020-12-17 DK DK20829365.4T patent/DK4076662T3/en active
- 2020-12-17 CN CN202080089867.2A patent/CN114929342A/en active Pending
- 2020-12-17 PT PT208293654T patent/PT4076662T/en unknown
- 2020-12-17 KR KR1020227024285A patent/KR20220114064A/en not_active Ceased
- 2020-12-17 CA CA3165148A patent/CA3165148A1/en active Pending
- 2020-12-17 JP JP2022536692A patent/JP7726883B2/en active Active
- 2020-12-17 JO JOP/2022/0155A patent/JOP20220155A1/en unknown
- 2020-12-17 IL IL293893A patent/IL293893A/en unknown
- 2020-12-17 HR HRP20240513TT patent/HRP20240513T1/en unknown
- 2020-12-17 HU HUE20829365A patent/HUE066235T2/en unknown
- 2020-12-17 MA MA58004A patent/MA58004B1/en unknown
- 2020-12-17 MX MX2022007350A patent/MX2022007350A/en unknown
- 2020-12-17 SI SI202030406T patent/SI4076662T1/en unknown
- 2020-12-17 LT LTEPPCT/IB2020/062144T patent/LT4076662T/en unknown
- 2020-12-17 ES ES20829365T patent/ES2987196T3/en active Active
- 2020-12-17 AU AU2020410531A patent/AU2020410531B2/en not_active Ceased
- 2020-12-18 TW TW109145169A patent/TW202136241A/en unknown
- 2020-12-21 AR ARP200103593A patent/AR120855A1/en not_active Application Discontinuation
-
2022
- 2022-06-15 EC ECSENADI202247876A patent/ECSP22047876A/en unknown
- 2022-06-15 DO DO2022000124A patent/DOP2022000124A/en unknown
- 2022-06-15 CO CONC2022/0008344A patent/CO2022008344A2/en unknown
- 2022-06-15 CL CL2022001625A patent/CL2022001625A1/en unknown
-
2024
- 2024-01-22 JP JP2024007468A patent/JP2024056707A/en not_active Withdrawn
-
2025
- 2025-06-06 JP JP2025095128A patent/JP2025143289A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT4076662T (en) | PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS | |
| PL3958977T3 (en) | CAMPTOTHECIN DERIVATIVES | |
| HUE056634T2 (en) | Substituted carbonucleoside derivatives are useful as anti-cancer agents | |
| DK3687999T3 (en) | RAPAMYCIN DERIVATIVES | |
| ZA201705092B (en) | Substituted nucleoside derivatives useful as anticancer agents | |
| BR112017015514A2 (en) | active polycyclic derivatives with pesticide-active sulfur-containing substituents | |
| IL254769B (en) | Nitrobenzyl derivatives of anti-cancer agents | |
| BR112017019371A2 (en) | pesticide-active tetracyclic derivatives with sulfur-containing substituents | |
| MA40770A (en) | MERGED IMIDAZOLES PENTACYCLIC DERIVATIVES | |
| BR112017019372A2 (en) | pesticide-active tetracyclic derivatives with sulfur-containing substituents | |
| UY35764A (en) | THE USE OF MACROCICLIC PICOLINAMIDS AS FUNGICIDES. | |
| UY36499A (en) | USE OF PICOLINAMIDS AS FUNGICIDES | |
| PT3539961T (en) | POLYCYCLIC AMIDE DERIVATIVES AS CDK9 INHIBITORS | |
| BR112017028600A2 (en) | active polycyclic derivatives with pesticide-active sulfur-containing substituents | |
| BR112018000052A2 (en) | pesticide-active polycyclic derivatives with sulfur-containing substituents | |
| PL3921307T3 (en) | Pyrazole derivatives | |
| EP3371163A4 (en) | PYRROLIDINE DERIVATIVES | |
| LT3680243T (en) | PENTACYCLIC COMPOUND | |
| EP3400220A4 (en) | PYRAZOLE DERIVATIVES | |
| PT4056557T (en) | BENZAZEPINE DERIVATIVES | |
| BR112016002560A2 (en) | pyrrolone derivatives used as herbicides. | |
| EP3312172A4 (en) | AMINOPYRAZOLE DERIVATIVES | |
| HUE054832T2 (en) | Pyridoimidazorifamycin derivatives as antibacterial agents | |
| EP3612172C0 (en) | ANTI-CANCER COMPOUNDS | |
| EP4003331A4 (en) | ANTI-CANCER |